Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

H3B-6527

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eisai

Drug class:

FGFR4 inhibitor

Related drugs:

FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	H3B-6527 Sensitive: C3 – Early Trials H3B-6527 Sensitive : C3	H3B-6527 Sensitive: C3 – Early Trials H3B-6527 Sensitive : C3
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	H3B-6527 Sensitive: D – Preclinical H3B-6527 Sensitive : D	H3B-6527 Sensitive: D – Preclinical H3B-6527 Sensitive : D
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	palbociclib + H3B-6527 Sensitive: D – Preclinical palbociclib + H3B-6527 Sensitive : D	palbociclib + H3B-6527 Sensitive: D – Preclinical palbociclib + H3B-6527 Sensitive : D